Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Non-Small Cell Lung Cancer: early-phase trial registry
206 of 455 indexed Non-Small Cell Lung Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #10 of 28,707 conditions by registered trial count.
455 US clinical trials · 206 currently recruiting · #10 of 28,707 conditions by registered trial count
Non-Small Cell Lung Cancer: 455 US clinical trials tracked, 206 recruiting.
Non-Small Cell Lung Cancer is the subject of 455 registered US clinical trials on ClinicalTrials.gov, 206 of them currently open to new participants. 65 are in Phase 3-4 (later-stage) and 327 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 24 of these trials.
Enrollment posture brief
Registry condition non-small-cell-lung-cancer
OPEN 206 | RECR 45% | LATE 65 | EARLY 327 | RANK #10 | SPON 24
Volume-matched condition peers
Nearest open-share peer: Gastric Cancer (45% recruiting · 159 trials)
Non-Small Cell Lung Cancer lists 206 open slots (45% of 455 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Non-Small Cell Lung Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Non-Small Cell Lung Cancer is recruiting above its size-band peers.
206 of 455 indexed trials (45.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Non-Small Cell Lung Cancer trials is spread across many organizations.
AstraZeneca accounts for 24 of 455 trials (5.3%). 242 distinct sponsors appear on at least one study for this condition label.
-
Typical Non-Small Cell Lung Cancer enrolment sits around 105 participants.
Median target enrolment is 105 among the 455 trials that report a genuine target (sentinel values excluded). 212 of those (46.6%) plan for fewer than 100 participants.
-
Non-Small Cell Lung Cancer research is mostly interventional.
414 interventional and 41 observational studies make up this index (91% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
455 total, page 5 of 10
KRAS-Targeted Vaccine With Nivolumab and Ipilimumab for Patients With NSCLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05254184
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
State University of New York - Upstate Medical University
NCT02619448
Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer
VA Ann Arbor Healthcare System
NCT05430009
Test-retest Evaluation of [18F]F-AraG PET
CellSight Technologies
NCT06084806
First-in-human Study of Interferon-y PET Imaging to Assess Response to Immunotherapy
Nerissa T. Viola
NCT06439914
A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
NCT06863233
Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects
Biodesix
NCT03289780
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
ImmunityBio
NCT03520686
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
Canadian Cancer Trials Group
NCT02273375
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
Klus Pharma
NCT04152499
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
Hoffmann-La Roche
NCT02486718
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
TScan Therapeutics
NCT05812027
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
AstraZeneca
NCT05221840
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
Gilead Sciences
NCT05502237
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche
NCT03178552
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
Regeneron Pharmaceuticals
NCT05800015
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Exelixis
NCT03170960
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
Daiichi Sankyo Co.
NCT03401385
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Eli Lilly and Company
NCT03157128
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
AstraZeneca
NCT03800134
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
Merck Sharp & Dohme
NCT03425643
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
Janssen Research & Development
NCT02609776
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
NCT06607185
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
OncoC4
NCT04140526
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
AstraZeneca
NCT04644068
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
BeiGene
NCT04746924
Precision Medicine Randomized Clinical Trial Comparing Molecular Tumor Board Assisted Care to Usual Care
Timothy Mullett
NCT05254795
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
Boehringer Ingelheim
NCT04886804
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
Daiichi Sankyo
NCT04656652
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Gilead Sciences
NCT05089734
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
AstraZeneca
NCT04035486
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
Asher Biotherapeutics
NCT05653882
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Hoffmann-La Roche
NCT02568267
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
Merck Sharp & Dohme
NCT04956692
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
AstraZeneca
NCT03334617
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
AbbVie
NCT05029882
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Agenus
NCT03860272
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Genentech
NCT04449874
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
NCT04623775
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
Eli Lilly and Company
NCT02152631
Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)
Razor Genomics
NCT01817192
MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment
Invitae Corporation
NCT05219734
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Pierre Fabre Medicament
NCT04913285
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
BeiGene
NCT05635708
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
AstraZeneca
NCT05120349
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
AstraZeneca
NCT04351555
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
Hoffmann-La Roche
NCT06497556
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
Dizal Pharmaceuticals
NCT05668988
Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
Dizal Pharmaceuticals
NCT03974022
Onco-primary Care Networking to Support TEAM-based Care
Duke University
NCT04258813
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 203 |
| Phase 2 | 124 |
| Phase 3 | 62 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Non-Small Cell Lung Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Non-Small Cell Lung Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Non-Small Cell Lung Cancer page
455 registered trials, 206 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 206 Non-Small Cell Lung Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AstraZeneca sponsors the most Non-Small Cell Lung Cancer trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-Small Cell Lung Cancer condition card totals 455 registered trials; most-linked intervention Carboplatin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.